Mounjaro (tirzepatide) is a once-weekly injection used in adults to support medical weight management and to treat type 2 diabetes. The way patients move through its dose range is a slow, structured process, set out in the UK Summary of Product Characteristics and followed by every UK prescriber. Understanding that process — and knowing what a clinician is actually looking at when they decide whether to step you up — makes the conversation at each review more useful.

How Mounjaro dose escalation works in the UK

Mounjaro comes as a pre-filled pen in six strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg, taken once a week. The titration pattern is the same for both the obesity and the type 2 diabetes indications: everyone starts at 2.5 mg weekly for four weeks. This first dose is a starter dose, not a full therapeutic one. Its job is to let the body adjust to tirzepatide before reaching the level at which weight loss really begins.

After those first four weeks, a clinician will typically step you up to 5 mg, again held for at least four weeks. Beyond 5 mg, increases happen in 2.5 mg increments, with at least four weeks at each step. The pattern is consistent for two clinical reasons: tirzepatide takes around four weeks to reach steady-state plasma levels at any given dose, and gastrointestinal side effects are most pronounced in the one to two weeks immediately after a change. Holding for a full month at each step gives the clinician a clear read on both response and tolerability before the next decision.

In the UK, Mounjaro is prescription-only, and every dose change is a decision made by a registered prescriber. It is neither safe nor licensed to step yourself up by switching pen strengths on your own. The BNF entry for tirzepatide sets out the cautions and contraindications that shape clinician decisions; the NHS medicines page is the patient-facing summary.

When clinicians typically step up the dose

After the initial 2.5 mg starter period, almost everyone who tolerates that first month will step up to 5 mg. From that point onwards, decisions become individual.

When deciding whether to step you up, a clinician will weigh several factors together: how much weight you have lost so far and whether that pace is in line with what would be expected at this stage; how well you are tolerating the current dose and whether side effects have settled; the starting BMI and the agreed clinical goal of treatment; and whether anything has changed in your medical picture — new medications, new diagnoses, new symptoms — that affects safety.

For weight management specifically, NICE guidance frames pharmacological treatment as a long-term intervention used alongside diet, activity and behavioural change. A clinician will not simply step you up because four weeks have passed. They will step you up because the current dose is doing less than it could and you can safely tolerate more.

Some patterns that come up in real consultations:

  • A patient who has lost weight steadily on 5 mg for two months but has now plateaued for three to four weeks. If they have tolerated 5 mg well, stepping to 7.5 mg is a reasonable next conversation.
  • A patient on 7.5 mg who is still losing weight at a steady pace and whose side effects have settled. Holding at 7.5 mg may be sensible until the response slows.
  • A patient on 5 mg who has already reached their agreed weight goal. Stepping up may not be appropriate — staying on a lower maintenance dose is the more thoughtful path.

Signs you may be ready for a higher dose

The signs below are prompts to discuss at your next review — not a checklist for you to act on by yourself.

You may be ready to discuss a dose increase if all of the following are true at once:

  • You have been at your current dose for at least four weeks.
  • Side effects from the last dose change have largely settled.
  • Your weight loss has plateaued for several consecutive weeks at the current dose, or it has slowed below an agreed pace.
  • You have not yet reached your weight or BMI goal as agreed with your clinician.
  • You are still some way below the maximum approved 15 mg dose.

A plateau on its own is not always a reason to increase. Your clinician will also look at non-medication factors — sleep, alcohol, resistance activity, the protein and fibre content of your meals, life stress, and other medications you are on. Sometimes the more productive change is at the lifestyle layer rather than the dose layer.

It is also worth saying clearly: every patient's curve is different. Some people see strong early weight loss and a flat plateau on a lower dose; others move more steadily across several doses. The trial-data averages in the SURMOUNT programme are exactly that — averages — and the right pace for you is one your clinician will help you read.

What to expect after a dose increase

When your dose is stepped up, your body reacts as if you are starting again. Most of the side effects you may have noticed in the first weeks of treatment are likely to return for a short period.

The most common reactions in the first one to two weeks after a dose change are:

  • Nausea, sometimes more noticeable around the day of the injection
  • Reduced appetite — part of how the medicine works
  • Constipation or, less commonly, loose stools
  • Fatigue or a general "off" feeling
  • Mild burping or reflux

For most people, these settle as the body adapts. Practical guidance that clinicians often share:

  • Eat smaller, more frequent meals.
  • Prioritise protein and fibre at every meal.
  • Drink water steadily through the day. Reduced appetite often blunts the urge to drink, but even mild dehydration can make nausea worse.
  • Be cautious with very rich or high-fat meals during the first two weeks of a new dose.
  • Plan your injection day around your schedule if you tend to feel effects strongly the day after.

If side effects are severe, anti-emetic options can be discussed with your clinician. Crucially, do not adjust your own dose to manage side effects. Stepping back down is a valid clinical option, but it should be a conversation, not a self-decision.

Rarely, more serious problems can occur, and these are listed in the BNF entry and the SmPC. Pancreatitis (severe persistent abdominal pain, often radiating to the back), gallbladder events, severe dehydration, and signs of an allergic reaction all warrant urgent clinical review. For true emergencies call 999; for urgent but non-emergency advice in the UK, call NHS 111.

When to stay at your current dose

Stepping up is not the only valid path. Many patients stay at a sub-maximum dose long-term, and for some that is the better answer.

You and your clinician may decide to hold at the current dose if:

  • You are continuing to lose weight at a steady, sustainable rate. There is no need to push higher just because you can.
  • You have reached your agreed clinical goal. From here the conversation moves to maintenance.
  • Side effects from a previous step have not fully settled, even after several weeks.
  • A new condition, a new medication, or a change in your life makes a higher dose less appropriate right now.
  • You have a history that warrants caution at higher doses — for example, prior gallbladder events.

A maintenance approach to GLP-1 treatment is a recognised pattern in UK clinical practice. The point of the medication is to support long-term metabolic and behavioural change, not to chase the highest dose.

Working with your Farmeci clinician

In a Farmeci programme you have a regular review with a UK-registered prescriber, usually about every four weeks while you are titrating. At each review your clinician will check your weight, your side-effect picture, your blood pressure where relevant, and your mood — because motivation and how you feel matter, not only the number on the scale. Honest answers help most: if a side effect is making the dose hard to live with, say so; if your weight has dropped quickly and you feel ready to slow down, say so. The decision about the next dose is a joint one, made on the basis of what is happening for you.

Patients who do best on GLP-1 treatment tend to be the ones who treat dose decisions as an ongoing conversation rather than a tick-box. Your clinician's role is to keep you safe, keep you informed, and translate the evidence — from NICE, the BNF, and the MHRA — into something that fits your life.